• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

NeoRx settles investor lawsuits

Article

Monoclonal antibody developer NeoRx of Seattle last month settled a lawsuit filed against it by shareholders.The litigation was related to a public stock offering made byNeoRx in December 1993 (SCAN 6/15/94). The settlement is for stockor a combination

Monoclonal antibody developer NeoRx of Seattle last month settled a lawsuit filed against it by shareholders.The litigation was related to a public stock offering made byNeoRx in December 1993 (SCAN 6/15/94). The settlement is for stockor a combination of stock and cash worth $1.5 million. A substantialportion of the settlement will be covered by insurance, the companysaid.

NeoRx last month also reported its financial results for 1994(end-December). The company reported a net loss of $11.1 millionon revenues of $1.6 million for the year, compared to a net lossof $8.5 million and revenues of $3.7 million in 1993.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.